![Dear Freddie](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Dear Freddie
Inversor de Capital Privado en Monograph Capital Advisors (UK) LLP .
Perfil
Freddie Dear is currently working as a Principal at Monograph Capital Advisors (UK) LLP since 2021.
He is also serving as the Vice President-Corporate Development at Ascend Gene & Cell Therapies Ltd.
since 2022.
Previously, Freddie worked as an Operations Director at Quell Therapeutics Ltd.
from 2019 to 2020.
He also held the position of Partner at Syncona Partners LLP from 2018 to 2021.
Freddie completed his undergraduate degree from The University of Edinburgh in 2016.
Cargos activos de Dear Freddie
Empresas | Cargo | Inicio |
---|---|---|
Monograph Capital Advisors (UK) LLP
![]() Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | Inversor de Capital Privado | 01/12/2021 |
Ascend Gene & Cell Therapies Ltd.
![]() Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | Corporate Officer/Principal | 01/12/2021 |
Antiguos cargos conocidos de Dear Freddie.
Empresas | Cargo | Fin |
---|---|---|
Syncona Partners LLP
![]() Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Inversor de Capital Privado | 31/12/2021 |
Quell Therapeutics Ltd.
![]() Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Director de Operaciones | 31/03/2020 |
Formación de Dear Freddie.
The University of Edinburgh | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 4 |
---|---|
Syncona Partners LLP
![]() Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Finance |
Quell Therapeutics Ltd.
![]() Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Health Technology |
Monograph Capital Advisors (UK) LLP
![]() Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | Finance |
Ascend Gene & Cell Therapies Ltd.
![]() Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | Commercial Services |
- Bolsa de valores
- Insiders
- Dear Freddie